

Satellite Symposia

Status as of 1 May 2018



WEDNESDAY, 13 JUNE 2018

18:15-19:45

Hall 3

Vindico Medical Education supported by
Bristol-Myers Squibb

Rheumatic complications of cancer immunotherapy: a new and emerging field in rheumatology

Chair(s):

Leonard H. Calabrese (United States)
Jan Leipe (Germany)
Xavier Mariette (France)

Introduction and pre-test	18:15
Biology of T cell exhaustion and the evolution of immune checkpoint inhibitors	18:25
Diagnosis and management of rheumatic irAEs from cancer immunotherapy	18:50
Clinical cases	19:15
Post-test and question and answer	19:35

18:15-19:45

Auditorium

AbbVie

RA treatment beyond the conventional: will JAK inhibitors disrupt our treatment paradigms?

Chair(s):

Peter Nash (Australia)

Peter Nash (Australia) 18:15
Welcome and introduction

John Isaacs (United Kingdom) 18:25
Influencing the JAK pathway: does selective inhibition make mechanistic sense?

Andrea Rubbert-Roth (Germany) 18:40
Beyond methotrexate: the role of JAK inhibitors when csDMARDs fail

Peter Nash (Australia) 19:00
Beyond biologics: JAK inhibitors as a novel alternative in bDMARD-IR patients

All 19:20
Panel discussion and Q&A

18:15-19:45

Elicium 2

Pfizer

Evolution or Revolution? How JAK inhibitors are changing the standard of care in RA

Chair(s):

Ronald van Vollenhoven (Netherlands)

Ronald van Vollenhoven (Netherlands) 18:15
Welcome and introductions
Where we are today: treatment trends in RA from the clinician's perspective

Eduardo Mysler (Argentina) 18:25
Proactive search: the best treatment for each patient

Ernest Choy (United Kingdom) 18:50
JAK inhibitors: novel therapies offering efficacious options for patients with RA

Torsten Witte (Germany) 19:15
Safety and real-world data offer a wider window into advanced therapies for patients with RA

Ronald van Vollenhoven (Netherlands) 19:40
RA therapy tomorrow: the road ahead

18:15-19:45 **Hall 7.2**

GSK

Leading the way towards a holistic approach to managing SLE

Welcome and introduction	18:15
Patient and physician priorities in SLE management	18:18
Why we shouldn't be tired of hearing about fatigue	18:30
Reducing long-term organ damage: Are we shooting for the moon?	19:00
Summing up and concluding remarks	19:30

18:15-19:45 **Forum**

Celltrion Healthcare

REdefining the future with InfixiMab bioSIMilAr

Chair(s):

Rieke Alten (Germany)

Rieke Alten (Germany) 18:15

Welcome and introduction

Laurent Grange (France) 18:20

Perspectives on living with rheumatic diseases

Rieke Alten (Germany) 18:35

Physicians' perspective on early introduction of biologics

Ki Chul Shin (Republic of Korea) 18:50

Drug retention of infliximab in ankylosing spondylitis: data from KOBIO

Rene Westhovens (Belgium) 19:05

Future of infliximab: introduction of the subcutaneous formulation

All 19:20

Panel discussion

18:15-19:45 **Emerald**

UCB

The reality of risk – how are we responding to fragility fracture in rheumatology?

Chair(s):

Socrates Papapoulos (Netherlands)

Socrates Papapoulos (Netherlands) 18:15

Why should we be vigilant for fragility fracture?

Ian Bruce (United Kingdom) 18:30

Ivo Vlaev (United Kingdom)

What are the complexities of decisions facing the rheumatologist? Clinical and behavioural perspectives

Ian Bruce (United Kingdom) 18:50

Socrates Papapoulos (Netherlands)

Improving the odds in fragility fracture: how can we act on risk factors in the rheumatology consultation?

Ivo Vlaev (United Kingdom) 19:10

How does our perception of risk influence how we make decisions in the rheumatology clinic?

Socrates Papapoulos (Netherlands) 19:20

Collaborative care in fragility fracture: recommendations for risk assessment and referral

All 19:30

Audience Q&A

18:15-19:45 **E106/E107**

IBSA

The treatment of OA: new concepts for an 'old' disease

Chair(s):

Cem Gabay (Switzerland)

Cem Gabay (Switzerland) 18:15

Welcome and introduction

Xavier Chevalier (France) 18:20

Treat to target in osteoarthritis: towards a better benefit/risk ratio of oral drugs

Cem Gabay (Switzerland) 18:40

Osteoarthritis of the hand: current evidence on its management

Jean Dudler (Switzerland) 19:00

Additional analysis on CONCEPT study data

Chiara Schiraldi (Italy) 19:15

Pharmaceutical-grade chondroitin sulphate vs food supplements: are they equivalent?

All 19:30

Question and answer session

Cem Gabay (Switzerland) 19:40

Concluding remarks

THURSDAY, 14 JUNE 2018

08:15-09:45

Hall 3

AbbVie**Transforming developments: the dynamic face of rheumatology****Chair(s):**

Ferry Breedveld (Netherlands)

Ferry Breedveld (Netherlands)

08:15

Welcome and introduction

Transforming treatments: how TNF inhibitors led the field in the biologic revolution

Boulos Haraoui (Canada)

08:30

Transforming standards: treat to target and the PASSIONate revolution

Wouter Bos (Netherlands)

08:45

Transforming outcomes: the role of patients in assessing their own disease

Lisa Olson (United States)

09:05

Transforming targets: drug discovery and development

All

09:25

Panel discussion and Q&A

08:15-09:45

Auditorium

Novartis**Making the invisible visible: the impact of IL-17A inhibition in psoriatic arthritis****Chair(s):**

Dafna Gladman (Canada)

Dafna Gladman (Canada)

08:15

Welcome and introductions

Georg Schett (Germany)

08:20

Enthesitis: the link between the skin and joints in PsA

Laura Coates (United Kingdom)

08:40

A 360 overview on the evolving unmet needs in PsA

Philip Conaghan (United Kingdom)

08:55

Insights into PsA from modern imaging

Philip Mease (United States)

09:10

GRAPPA treatment recommendations: are they met with IL-17A inhibition?

All

09:30

Panel discussion and conclusions

08:15-09:45

Elicium 2

Lilly**IL-17A inhibition: optimising the PsA management****Chair(s):**

Michael Nurmohamed (Netherlands)

Michael Nurmohamed (Netherlands)

08:15

Welcome and introduction

Helena Marzo-Ortega (United Kingdom)

08:20

Is the management of patients with PsA optimal?

Frank Behrens (Germany)

08:35

Overview of ixekizumab benefits and safety results

Diamant Thaçi (Germany)

08:50

Peter Nash (Australia)

PsA management in the real world: the rheumatologist and dermatologist perspective

All

09:20

Panel discussion

Michael Nurmohamed (Netherlands)

09:30

Summary and symposium close

08:15-09:45

Hall 7.2

Roche**Journey from clinical trials to patient care****Chair(s):**

Ernest Choy (United Kingdom)

Ernest Choy (United Kingdom)

08:15

Welcome & introduction

Ernest Choy (United Kingdom)

08:20

Exploring the value of real-world evidence (RWE)

Deborah Symmons (United Kingdom)

08:30

Confidence in treating the at-risk and elderly population

Fabrizio de Benedetti (Italy)

08:50

Advancing knowledge of the paediatric population

Frank Buttgereit (Germany)

09:10

Optimising the use of glucocorticoids in clinical practice

Ernest Choy (United Kingdom)

09:30

Summary

All Faculty

09:35

Question & answer session

08:15-09:45 Forum

Biogen

Anti-TNF in rheumatic diseases: inventory and outlook

Chair(s):

Peter Taylor (United Kingdom)

Peter Taylor (United Kingdom) 08:15

Opening, intro & overview: the treatment landscape in RA

Short presentations integrated at various time points into an interactive faculty/audience discussion

Raj Sengupta (United Kingdom)

Preparing a switch: the perfect time to re-evaluate the clinical status of patients with RA/AS

Paul Enck (Germany)

Preparing a switch: the perfect time to re-evaluate the patient's psychosocial status

Juergen Braun (Germany)

Successful switching: shared decision making with the patient is critical

Glenn Haugeberg (Norway)

Post-switch patient follow-up in busy daily clinical practice - opportunities and challenges of remote patient monitoring

All 09:40

Summary and conclusion

08:15-09:45 Amtrium

medac

Methotrexate – new insights into the anchor drug

Chair(s):

Daniel Aletaha (Austria)

Daniel Aletaha (Austria)

Benefits of subcutaneous MTX in daily practice

Jens Thiel (Germany)

Relevance of the microbiome for RA treatment outcomes

Ronald van Vollenhoven (Netherlands)

JAK-inhibitors: will they change the treatment paradigm?

Ivan Foeldvari (Germany)

How to optimize JIA treatment

08:15-09:45 Emerald

Menarini

Multimodal approach for acute pain in rheumatology - a new paradigm targeting multiple mechanisms

Chair(s):

Serge Perrot (France)

Serge Perrot (France) 08:15

Introduction

Stefano Coaccioli (Italy) 08:30

Low back pain and osteoarthritis: from clinical features to complex mechanisms

Serge Perrot (France) 08:50

Multimodal approach, a step forward in the current therapeutic strategy

Magdi Hanna (United Kingdom) 09:10

Rationale of the new oral fixed dose combination of dexketoprofen/Tramadol in targeting multiple mechanisms of moderate to severe acute pain

Discussion and final remarks 08:15

08:15-09:45 E106/E107

Amgen

Ready for the next biosimilar? Key stakeholder insights to guide choice

Chair(s):

Thierry Thomas (France)

Fernando Perez-Ruiz (Spain)

Thierry Thomas (France) 08:15

Welcome and introduction

Murray Aitken (United States) 08:25

Assessing biosimilar attitudes and use: a marketplace evaluation

Fernando Perez-Ruiz (Spain) 08:45

Clinical perspectives: what to consider when selecting the next anti-TNF biosimilar

Alison Kent (United Kingdom) 09:10

Patient perspectives on anti-TNF biosimilars: understanding attitudes, beliefs and expectations

All 09:30

Panel discussion

Fernando Perez-Ruiz (Spain) 09:40

Closing remarks

17:30-19:00 Auditorium**AbbVie****Solving the patient puzzle: a pragmatic approach to SpA management****Chair(s):**

Georg Schett (Germany)

Georg Schett (Germany) 17:30

Welcome and introduction

The many faces of SpA: how does inflammation lead to multifaceted disease?

Denis Poddubnyy (Germany) 17:45

Disease progression: under control or still a cause for concern?

Philip Mease (United States) 18:05

Optimising long-term treatment: lessons from clinical practice

Dirk Elewaut (Belgium) 18:25

Integrated care: a practical approach to patient management

All 18:45

Panel discussion and Q&A

17:30-19:00 Hall 7.2**Pfizer****How to detect and treat unresolved symptoms in the patient with psoriatic arthritis****Chair(s):**

Désirée van der Heijde (Netherlands)

Désirée van der Heijde (Netherlands) 17:30

Welcome and introductions

Laure Gossec (France) 17:35

Diagnostic 'hot spots': defining targets, detecting patients' symptoms

Enrique Soriano (Argentina) 17:55

New products, new opportunities in PsA

Frank Behrens (Germany) 18:20

Optimising treatments: the physician and nurse practitioner partnership

Désirée van der Heijde (Netherlands) 18:40

Audience Q&A/panel discussion summary and close

17:30-19:00 Forum**Sanofi Genzyme****The challenges of multi-morbidities in RA: IL-6 and chronic inflammation****Chair(s):**

Peter Taylor (United Kingdom)

Peter Taylor (United Kingdom) 17:30

Meeting the challenge of multi-morbidities in RA

Michael Nurmohamed (Netherlands) 17:40

Multi-morbidities associated with RA: defining the systemic manifestations of the disease

Ernest Choy (United Kingdom) 17:55

The multi-faceted role of IL-6 in RA and other RA-associated conditions

Mark Genovese (United States) 18:15

The effects of IL-6R blockade inside and outside the RA joint

All 18:35

Moderated discussion with faculty and audience Q&A

Peter Taylor (United Kingdom) 18:55

Close

17:30-19:00 Amtrium**Janssen****A practical guide to new treatments in psoriatic arthritis and psoriasis****Chair(s):**

Dennis McGonagle (United Kingdom)

Costantino Pitzalis (United Kingdom)

Dennis McGonagle (United Kingdom) 17:30**Costantino Pitzalis (United Kingdom)**

Welcome and introduction

Costantino Pitzalis (United Kingdom) 17:35

Pathophysiology of joint and skin diseases and implications for treatment

Lluis Puig (Spain) 17:55

Lessons from the skin: therapeutic options for psoriasis in clinical practice

Dennis McGonagle (United Kingdom) 18:20

Lessons from the joint: therapeutic options for psoriatic arthritis in clinical practice

All 18:45

Q&A

Conclusions and close of meeting **18:55**

17:30-19:00

Emerald

Bristol-Myers Squibb**Modulating the wayward T cell: the new horizon in autoimmunity and cancer****Chair(s):**

Leonard Calabrese (United States)

Leonard Calabrese (United States) 17:45

Welcome and introduction

Leonard Calabrese (United States) 17:47

T-cell co-stimulation in health and disease

Roberto Caporali (Italy) 18:12

T cell-B cell communication in autoimmune diseases, with a focus on RA

Christian Blank (Netherlands) 18:37

Expanding our understanding of T-cell modulation through learnings from cancer

All 19:02

Panel discussion and Q&A

17:30-19:00

E106/E107

Samsung Bioepis**The era of biosimilars: reshaping the healthcare environment****Chair(s):**

Josef Smolen (Austria)

Josef Smolen (Austria) 17:30

Welcome and introduction

Josef Smolen (Austria) 17:40

Anti-TNF biosimilars in rheumatology

João Gonçalves (Portugal) 17:55

Reinvestigating biologics quality excellence

Mark Quinn (United Kingdom) 18:10

Biosimilar adoption: improving rheumatology services for patients

Fabrizio Benedetti (Italy) 18:25

Understanding the placebo effect

All 18:40

Q&A

Josef Smolen (Austria) 18:50

Closing

FRIDAY, 15 JUNE 2018

08:15-09:45

Auditorium

Lilly**Challenging the rheumatoid arthritis treatment standards with JAK inhibitors****Chair(s):**

Désirée van der Heijde (Netherlands),

Mark C. Genovese (United States)

Désirée van der Heijde (Netherlands) 08:15**Mark C. Genovese (United States)**

Welcome and introduction

Peter Taylor (United Kingdom) 08:20

JAK inhibitors - are they all the same?

Paul Emery (United Kingdom) 08:35

JAK inhibitor baricitinib: how is it different from the standard of care (anti-TNF)?

Ronald van Vollenhoven (Netherlands) 08:50

JAK inhibitors position in the treatment algorithm of rheumatoid arthritis

Ulf Müller-Ladner (Germany) 09:05

JAK inhibitors in clinical practice

Désirée van der Heijde (Netherlands) 09:20**Mark C. Genovese (United States)**

Panel discussion and Q&A

Symposium close 09:45

08:15-09:45

Elicium 2

Novartis**IL-17A inhibition in axial spondyloarthritis: new insights and implications for clinical practice****Chair(s):**

Filip van den Bosch (Belgium)

Filip van den Bosch (Belgium) 08:15

Welcome and introductions

Merryn Jongkees (Netherlands) 08:20

Axial spondyloarthritis: what matters to a patient?

Atul Deodhar (United States) 08:35

Clinical intervention in axial spondyloarthritis: why, when and how?

Rik Lories (Belgium) 08:55

Underlying pathophysiology of axial spondyloarthritis: clinical assessments and implications

Xenofon Baraliakos (Germany) 09:10

IL-17A inhibition in axial spondyloarthritis: current and future perspectives

All 09:30

Panel discussion and conclusions

08:15-09:45 Forum**Integritas supported by Gilead Sciences, Inc.****Clinical issues in rheumatoid arthritis: discussions and debates on the evolving roles of targeted synthetic DMARDs****Chair(s):**

Rieke Alten (Germany)

Rieke Alten (Germany) 08:15

Welcome and pre-activity questionnaire

Josef Smolen (Austria) 08:20

Pathophysiology: a focus on JAK enzymes

Joel Kremer (United States) 08:35

Long-term assessment of patient with RA: understanding treatment targets as a foundation for therapeutic tailoring

Rieke Alten (Germany) 08:55

Targeted synthetic DMARDs in the treatment of RA

All 09:15

Case study panel discussion: putting the evidence to practice

All 09:30

Post-activity questionnaire and Q&A session

08:15-09:45 Amtrium**UCB****Axial spondyloarthritis in 2018: new data, less compromise?****Chair(s):**

Martin Rudwaleit (Germany)

Martin Rudwaleit (Germany) 08:15

Welcome and introduction from the symposium chair

Lianne Gensler (United States) 08:20

Diagnostic delay, establishing disease control and starting a family

Maxime Dougados (France) 08:45

The right management strategy for the right patient

Denis Poddubnyy (Germany) 09:05

Taking control of structural damage progression and exploring new horizons

Martin Rudwaleit (Germany) 09:25

Wrap-up and conclusion

All 09:40

Question and answer session moderated by the symposium chair

08:15-09:45 Emerald**Celgene****Towards a targeted approach in psoriatic arthritis with PDE4 inhibition****Chair(s):**

Laure Gossec (France)

Laure Gossec (France) 08:15

Opening statement

Laure Gossec (France) 08:20

Guidelines in evolution and their applicability in treatment decisions

Frank Behrens (Germany) 08:35

Evidence from homogeneous clinical trials for a diverse patient population – the challenge in PsA patient care

Philip J. Mease (United States) 09:00Optimising the clinical utility of PDE4 inhibition
Audience Q&A**Laure Gossec (France) 09:20**

Summary and close

08:15-09:45 E106/E107**Boehringer Ingelheim****Interstitial lung disease in autoimmune rheumatic diseases – moving towards better patient care****Chair(s):**

Frank van den Hoogen (Netherlands)

Frank van den Hoogen (Netherlands) 08:15

How relevant is ILD in autoimmune rheumatic diseases?

Athol Wells (United Kingdom) 08:25

How should we diagnose and monitor ILD?

Christopher Denton (United Kingdom) 08:45

Treatment of ILD in autoimmune rheumatic diseases

Jörg Distler (Germany) 09:05

Future perspectives on the treatment of fibrosis

All 09:25

Questions and answers

17:30-19:00 Auditorium

Pfizer

Unraveling chronic pain: from defining to modulating

Chair(s):

Francis Berenbaum (France)

Francis Berenbaum (France) 17:30

Welcome and faculty introductions

Francis Berenbaum (France) 17:35

Defining the humanistic and societal burden of chronic pain

Martin Koltzenburg (United Kingdom) 17:55

Overview of pain pathways and mediators of pain sensitization

Richard Langford (United Kingdom) 18:20

Current and future approaches to modulate chronic pain

All 18:45

Panel discussion and Q&A

Francis Berenbaum (France) 18:55

Closing remarks

17:30-19:00 Forum

RMEI supported by Sanofi Genzyme & Regeneron

Global perspectives in RA: the role of new biologics for optimal management

Chair(s):

Paul Emery (United Kingdom)

Speakers:

Paul Emery (United Kingdom)

Leonard H. Calabrese (United States)

Josef F. Smolen (Austria)

Paul Emery (United Kingdom) 17:30

Introductions and overview of panel topics

Faculty Panel Discussion #1 17:40

The patient with RA who fails to respond

Faculty Panel Discussion #2 18:05

The patient with RA who becomes non-responsive

Faculty Panel Discussion #3 18:30

The patient with poor response and comorbidities

Paul Emery (United Kingdom) 18:55

Summary remarks

17:30-19:00 Amtrium

Rheumatology Today

Highlights of EULAR 2018

Chair(s):

Matthias Schneider (Germany)

Speakers:

Peer M. Aries (Germany)

Xenofon Baraliakos (Germany)

Frank Behrens (Germany)

Christof Iking-Konert (Germany)

Christof Specker (Germany)

Torsten Witte (Germany)

Round table experts:

Frank Buttgereit (Germany)

Jens Gert Kuipers (Germany)

Ulf Müller-Ladner (Germany)

Presentation of six trials presented at EULAR 2018 featuring the following topics:

- Axial spondylarthritis
- Biologica monotherapy
- Collagenoses
- Novelities in RA treatment
- Psoriatic arthritis
- Vasculitis

17:30-19:00 Emerald

Janssen

Lupus: now and in the future

Chair(s):

David Isenberg (United Kingdom)

Ronald van Vollenhoven (Netherlands)

David Isenberg (United Kingdom) 17:30

Angela Tincani (Italy)

Welcome and introduction

Eisabet Svenungsson (Sweden) 17:40

Current options: limitations of current treatment in lupus

Ronald van Vollenhoven (Netherlands) 18:00

How to assess lupus in clinical care

David Isenberg (United Kingdom) 18:20

Biologics: what's coming next?

David Isenberg (United Kingdom) 18:40

Elisabet Svenungsson (Sweden)

Angela Tincani (Italy)

Ronald van Vollenhoven (Netherlands)

Panel discussion

Angela Tincani (Italy) 18:55

Ronald van Vollenhoven (Netherlands)

Conclusions and close of meeting

17:30-19:00

E106/E107

Menarini**Hyperuricemia with deposition:
a multisystemic disease****Chair(s):**

Fernando Perez-Ruiz (Spain)

Fernando Perez-Ruiz (Spain)

Introduction

Claudio Borghi (Italy)

Hyperuricemia with deposition: a cardio metabolic disorder

Leonardo Punzi

Interaction between hyperuricemia with deposition and rheumatic diseases

Fernando Perez-Ruiz (Spain)

Hyperuricemia with deposition: the importance of adherence to treatment

Fernando Perez-Ruiz (Spain)

Summary and meeting close